 |
인쇄하기
취소
|
Therapeutic potential of GV1001 analyzed in international scientific journal
A flurry of articles were published on GV1001, a pancreatic cancer treatment developed Korea-based developer KAEL-GemVax.
Recently, the results of CPP (cell-penetrating peptide) related study on GV1001 was published in the latest issue of the international scientific journal Biomaterials (impact factor 8.496).
GV1001 peptide can be penetrated various cell membranes and be accumulated in t...
Recently, the results of CPP (cell-penetrating peptide) related study on GV1001 was published in the latest issue of the international scientific journal Biomaterials (impact factor 8.496).
GV1001 peptide can be penetrated various cell membranes and be accumulated in t...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.